Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Health Issues
Monitored issues related to pharmaceutical prices. Issues regarding the pharmaceutical and medical device supply chain. Monitored issues concerning drug shortages. Issues concerning the reauthorization of Pandemic and All-Hazards Preparedness and Response Act (PAHPA). Monitored AI issues. Cybersecurity issues and S. 4939, Countering CCP Act. Issues concerning emergency preparedness and essential medical supplies. Issues concerning regulatory reforms.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · third_quarter · Health Issues
Issues related to Privacy Legislation Issues related to remanufacturing and servicing medical devices Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 1539 - the Medical Device Electronic Labeling Act Issues related to National Defense Authorization Act Issues related to FDA regulation of diagnostic tests Issues related to the Countering CCP Act (S. 4939) Issues related to the Health Care Cybersecurity and Resiliency Act of 2025 (S. 3315)
Client expense: $1,080,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · third_quarter · Science/Technology
H.R. 2683, Remote Access Security Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9592, American Space Leadership for the 21st Century Act, all provisions. H.R. 10670, China FIREWALL Act, all provisions. H.R. 10695, United States Submarine Cable Security Policy Act of 2026, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4939, Countering CCP Act, all provisions. S. 5316, Biotech Investment National Security Act (BINSA), all provisions. Issues Related to Adversarial Distillation of American AI Models; Chinese Biotech Industry and Dual-Use Threats; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; National Security Capabilities of Advanced AI Systems; NATO Cybersecurity Capabilities and Strategy; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; TikTok Operations and Safeguards; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy and Regulation; U.S. Cybersecurity Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Open Technology Fund; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy; and U.S. Technology-Security Strategy (no bill).
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Issues related to Privacy Legislation Issues related to remanufacturing and servicing medical devices Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 1539 - the Medical Device Electronic Labeling Act Issues related to National Defense Authorization Act Issues related to FDA regulation of diagnostic tests Issues related to the Countering CCP Act (S. 4939) Issues related to the Health Care Cybersecurity and Resiliency Act of 2025 (S. 3315)
Client expense: $971,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · second_quarter · Health Issues
Monitored issues related to pharmaceutical prices. Issues regarding the pharmaceutical and medical device supply chain. Monitored issues concerning drug shortages. Issues concerning the reauthorization of Pandemic and All-Hazards Preparedness and Response Act (PAHPA). Monitored AI issues. Cybersecurity issues and S. 4939, Countering CCP Act. Issues concerning emergency preparedness and essential medical supplies. Issues concerning regulatory reforms.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office